Publication | Open Access
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
42
Citations
17
References
2023
Year
ClinicalTrials.gov Identifier: NCT03635567.
| Year | Citations | |
|---|---|---|
Page 1
Page 1